Verona Pharma

VERONA PHARMA PLC - ADR

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

News

Intraday Update

Markets

Movers

Trading Ideas

ALTM

ARRY

FSLR

HYLN

LAAC

LQDA

OSCR

PLAY

SEDG

SGML

VRNA

WOOF

Petco, AppLovin, Dave &amp; Buster&#39;s And Other Big Stocks Moving Higher On Wednesday

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

Large Cap

Health Care

General

GSK&#39;s Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

GSK&#39;s Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker&#39;s Lungs, Prepares Competition With Amgen/AstraZeneca&#39;s Drug

Lab.People.Healthcare.thisisengineering-raeng-JzdrZzZ50tA-unsplash-copy

Short Ideas

Pre-Market Outlook

CPRX

Top 3 Health Care Stocks That May Crash In August

Verona Pharma plc - American Depositary Shares

Verona Pharma PLC

Earnings

Press Releases

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Present at Jefferies London Healthcare Conference

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Verona Pharma Announces December 2024 Investor Conference Participation

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Financing

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Xeris Announces Changes to Its Board of Directors

AGEN

LGND

TVTX

VKTX

XERS

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Verona Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga